Humanin is a 24-amino-acid peptide found in 2001 in a search for factors that protect nerve cells from Alzheimer’s-related death. It is one of the mitochondrial-derived peptides. It has been studied in cells, worms and rodents, and its levels have been measured in people. This guide covers its structure, proposed mechanism, research findings and status. Sources were checked on November 17, 2026.
Quick answer: Humanin is a naturally occurring peptide, not an approved drug. The mitochondrial genome contains a reading frame for it, which is why it is grouped with mitochondrial-derived peptides. In lab studies it blocked cell death and bound the cell-death protein Bax. Human data so far are observational, such as lower blood levels with age.
Vitrapep does not sell humanin; this page is a reference summary of published research and regulatory information.
What is humanin?
Humanin is a linear peptide of 24 amino acids. PubChem lists its sequence as MAPRGFSCLLLLTSEIDLPVKRRA. It gives the formula C119H204N34O32S2 and a molecular weight of 2,687.2 g/mol (PubChem CID 16131438). It counts as a peptide because it is a short chain of amino acids. Our peptide primer explains the basics.
Hashimoto and colleagues identified it in 2001 using functional expression screening. In cell culture, it abolished nerve-cell death caused by several familial Alzheimer’s disease genes and by amyloid beta (Hashimoto et al., 2001). It did not block cell death from every cause tested.
In 2003, Guo and colleagues reported that the mitochondrial genome contains an identical open reading frame. They proposed that humanin originated in mitochondria (Guo et al., 2003). Later papers call it a mitochondrial derived peptide (Yen et al., 2020). Our mitochondrial peptides overview covers this group, which also includes MOTS-c.
Humanin: key facts
| Fact | Detail |
|---|---|
| Structure type | Linear peptide of 24 amino acids |
| Class | Mitochondrial-derived peptide (naturally occurring) |
| Molecular formula | C119H204N34O32S2 |
| Molecular weight | 2,687.2 g/mol |
| Development stage | Preclinical; no registered interventional human trial (2026) |
| Sponsor or developer | No company sponsor found; studied by academic laboratories |
How does humanin work?
The best-described mechanism involves Bax, a protein that triggers apoptosis, or programmed cell death. Guo and colleagues found that humanin binds Bax and stops it from moving from the cell fluid to mitochondria. Lowering humanin levels made cells more sensitive to Bax (Guo et al., 2003). These experiments used cultured cells and isolated mitochondria.
A second line of work concerns metabolism. In rodents, humanin acting in the brain improved overall insulin sensitivity, and this effect depended on hypothalamic STAT-3 signaling. A potent humanin analog lowered blood glucose in Zucker diabetic fatty rats (Muzumdar et al., 2009). The same paper reported that circulating humanin declined with age in humans and mice. Animal studies often use HNG, which Yen and colleagues describe as a potent humanin analog.
What is humanin being studied for?
Humanin is not approved by the FDA for any use. ClinicalTrials.gov lists 7 studies that mention humanin (ClinicalTrials.gov). None gives humanin as a treatment. Examples include:
- humanin forms in heart muscle and plasma and complications after cardiac surgery, observational, 106 people, University of Tartu, completed 2019 (NCT03431844);
- plasma humanin in acute kidney injury, observational, Guangdong Provincial People’s Hospital (NCT06105229); and
- a 2026 comparison of two anesthesia methods that measures ferroptosis, humanin and MOTS-c levels in kidney transplant recipients, University of Gaziantep (NCT07678073).
In published research, humanin is studied mainly in relation to Alzheimer’s disease, insulin action and aging. In those papers it is a research subject or a measured biomarker, not a tested medicine.
What does the research show?
Cell studies. The 2001 discovery paper showed protection of cultured nerve cells against several Alzheimer’s-related insults (Hashimoto et al., 2001). The 2003 Bax work was also in cells and cell-free systems.
Lifespan and healthspan. A 2020 study combined several species (Yen et al., 2020). In the roundworm C. elegans, extra humanin increased lifespan, and this depended on the daf-16/Foxo pathway. Mice engineered to make more humanin showed greater protection against toxic insults. Middle-aged mice treated with HNG had improved metabolic healthspan measures and fewer inflammatory markers. In people, circulating humanin was higher in children of centenarians than in age-matched controls. Levels were lower in Alzheimer’s disease and in MELAS, a mitochondrial disease. The human findings are observational.
A genetic variant. A 2024 study reported that a humanin variant called P3S was enriched in centenarians who carry the APOE4 gene variant. In mice engineered to develop amyloid with APOE4, P3S reduced brain amyloid-beta buildup more than standard humanin did (Miller et al., 2024). The human part of that work was genetic and transcriptomic, not a treatment trial.
What side effects have studies reported?
We found no published adverse event data from people given humanin. ClinicalTrials.gov lists no interventional trial of humanin, so no registry safety results exist. The papers above report effects in cells and animals; they do not establish safety in humans. Any statement about humanin side effects in people would go beyond the published evidence we found.
What is humanin’s regulatory status, and how is it used in research?
Humanin has no FDA approval. A search of fda.gov returned no FDA document naming it, so we found no approval, warning letter or designation to report. It is not the subject of any registered drug-development program we could find.
In laboratories, humanin and its analog HNG are tools for studying cell survival, insulin action and aging in cells and animals. A research-use-only label does not make a compound safe or approved; see research use only, explained. For related compounds, see MOTS-c and SS-31.
Frequently asked questions about humanin
Is humanin a peptide?
Yes. It is a linear chain of 24 amino acids, with a molecular weight of 2,687.2 g/mol.
Why is humanin called a mitochondrial-derived peptide?
The mitochondrial genome contains an open reading frame identical to the humanin sequence. Guo and colleagues proposed in 2003 that it originated in mitochondria.
Is humanin FDA approved?
No. We found no FDA approval, designation or registered drug-development trial for humanin.
Has humanin been tested in humans?
Not as a treatment in any registered trial we found. Human studies so far measure its levels in blood or tissue.
What is HNG?
HNG is a potent humanin analog used in animal studies, including the 2020 healthspan work in middle-aged mice.
What to know now
- Structure: linear peptide of 24 amino acids; 2,687.2 g/mol.
- Origin: found in 2001; matching reading frame in the mitochondrial genome.
- Mechanism: binds Bax and blocks its move to mitochondria (cell studies).
- Evidence: cells, worms and mice; human data are observational.
- Status: not FDA-approved; no registered interventional human trial.
- Safety: no human adverse event data found.
What we’re watching
Results from registered studies that measure humanin, including the 2026 kidney transplant anesthesia study. Any first registered trial that gives humanin or an analog to people. Related guides: MOTS-c, SS-31 and the mitochondrial peptides overview.